BridgeMD
New treatment option for Smoking-related Pathology
Official title Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway
ClinicalTrials.gov ID: NCT06387017
What this study is testing
- What it's testing
- Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 to 80
You may be able to join if
- 1- All PREVALUNG or PREVALUNG ETOILE participants
- 2- Active or former smokers who have smoked daily for at least 10 years and have either atheromatous disease (coronary, lower limb, supra-aortic...
- Age 45- 75 years and
- Medical follow-up for smoking-related atheromatous pathology and
- daily smoking for at least 10 years prior to disease (for smoking, there are no quantitative criteria or withdrawal times)
You likely can't join if
- cancer history \< 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma...
- symptoms of lung cancer (involuntary weight loss \> 7 kg in 1 year, hemoptysis)
- known history of pulmonary nodule requiring specialized follow-up
- history of pulmonary fibrosis or pulmonary hypertension
- active pulmonary parenchymal infection
- severe cardiac or respiratory insufficiency (rest dyspnea)
See the full eligibility criteria
- 1- All PREVALUNG or PREVALUNG ETOILE participants
- 2- Active or former smokers who have smoked daily for at least 10 years and have either atheromatous disease (coronary, lower limb, supra-aortic trunk, aortic, visceral or upper limb arteries) or a moderate or high...
- Age 45- 75 years and
- Medical follow-up for smoking-related atheromatous pathology and
- daily smoking for at least 10 years prior to disease (for smoking, there are no quantitative criteria or withdrawal times)
- visual coronary calcium score quantified by a radiologist on a chest CT scan. 3- Individuals at risk of lung cancer without atheromatous disease or moderate or high calcium score being managed for a tobacco-related...
- Age 45- 75 and
- Medical follow-up for a smoking-related pathology:
- chronic obstructive pulmonary disease / emphysema, or
- history of non-progressive cancer \> 5 years, including ENT, lung, breast, cervix, excreto-urinary tract, bladder, esophagus, stomach, pancreas, liver, kidney, chronic myeloid leukemia. and \- daily smoking for at least...
- Age 55 - 74
- Cumulative smoking ≥ 30 pack-years
- active or weaned for less than 15 years Or NELSON
- Age 50-75
- Smoking :
- \> 15 cigarettes /D for more than 25 years or
- \> 10 cigarettes /D for more than 30 years
- active smoking or cessation \< 10 years Or American recommendations :
- Age 50 - 80
- Smoking ≥20 PA
- cancer history \< 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer...
- symptoms of lung cancer (involuntary weight loss \> 7 kg in 1 year, hemoptysis)
- known history of pulmonary nodule requiring specialized follow-up
- history of pulmonary fibrosis or pulmonary hypertension
- active pulmonary parenchymal infection
- severe cardiac or respiratory insufficiency (rest dyspnea)
- performance status (WHO) 2, 3 or 4
- patient not affiliated to the social security system (beneficiary or beneficiary's beneficiary)
- patient deprived of liberty
- patients under guardianship or trusteeship
- pregnant or breast-feeding women
The study team makes the final eligibility decision.
Where it's taking place
- Marseille, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 45 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Marseille, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.